Drugs / GCAR1
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 04 trials | ||||||
| Phase 0 | NCT07104682 | Aug 2025 → Nov 2026 expected | alveolar soft part sarcoma | University of Calgary | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06813417 | Jan 2025 → Jan 2030 expected | alveolar soft part sarcoma | University of Calgary | Active not recruiting | No outcome recorded |
| Phase 0 | NCT06789081 | Feb 2024 → Mar 2028 expected | alveolar soft part sarcoma | AHS Cancer Control Alberta | Active not recruiting | No outcome recorded |
| Phase 0 | NCT06827886 | Sep 2023 → Sep 2024 | alveolar soft part sarcoma | AHS Cancer Control Alberta | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT07297667 | Jun 2026 → Dec 2028 expected | alveolar soft part sarcoma, renal cell carcinoma, triple-negative breast carcinoma | Canadian Cancer Trials Group | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GCAR 1 | “GCAR 1 is a patient-specific cell therapy product containing a mixture of autologous lymphocytes transduced with a lentiviral vector containing a chimeric antigen receptor...” NCT06827886 ↗6“GCAR 1 is a patient-specific cell therapy product containing a mixture of autologous lymphocytes transduced with a lentiviral vector containing a chimeric antigen receptor...” NCT06789081 ↗ |
| Action | Deplete | “promote the elimination of target cells” NCT06813417 ↗ |
| Modality | Cell therapy | “patient-specific cell therapy product” NCT06813417 ↗ |
| Route | Intravenous | “two separate intravenous infusions” NCT06813417 ↗ |
| Target | GPNMB | “targeting GPNMB” NCT06813417 ↗ |